Clinical characteristics and prognostic value of pre-retreatment plasma Epstein-Barr virus DNA in locoregional recurrent nasopharyngeal carcinoma

Ming-Zhu Liu1,2,3,4 | Shuo-Gui Fang1,2,3,4 | Wei Huang1,2,3,4 | Han-Yu Wang1,2,3,4 | Yun-Ming Tian5 | Run-Da Huang1,2,3,4 | Zhuang Sun1,2,3,4 | Chong Zhao1,2,3,4 | Tai-Xiang Lu1,2,3,4 | Ying Huang1,2,3,4 | Fei Han1,2,3,4

1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, People’s Republic of China
2State Key Laboratory of Oncology in South China, Guangzhou, Guangdong Province, People’s Republic of China
3Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong Province, People’s Republic of China
4Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong Province, People’s Republic of China
5Department of Radiation Oncology, Huizhou Municipal Centre Hospital, Huizhou, Guangdong Province, People’s Republic of China

Abstract

Purpose: To define the clinical characteristics and prognostic value of pre-retreatment plasma Epstein-Barr virus (EBV) DNA, we investigated EBV status in locoregional recurrent nasopharyngeal carcinoma (lrNPC) patients.

Methods: Between April 2008 and August 2016, the data of patients with nonmetastatic lrNPC were retrospectively reviewed. The survival indexes of patients between different pre-retreatment EBV status groups were compared.

Results: A total of 401 patients with nonmetastatic lrNPC were enrolled, and 197 (49.1%) patients had detectable pre-retreatment plasma EBV DNA. Treatment included radiotherapy alone (n = 37 patients), surgery alone (n = 105), radiotherapy (n = 208), surgery combined with radiotherapy (n = 20), chemotherapy and targeted therapy (n = 31). Median follow-up was 32 months. The 3-year locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and overall survival (OS) rates for the entire cohort were 64.8%, 89.4%, and 58.8%, respectively. The estimated 3-year LRRFS, DMFS, and OS rates for the pre EBV-positive group vs the pre EBV-negative group were 54.2% vs 75.0% (P < 0.001), 86.6% vs 91.9% (P = 0.05), 51.6% vs 65.9% (P = 0.01), respectively. Among patients in the clinical stage rI/II, there were 17 patients in the radiotherapy alone group and 49 patients in the surgery alone group. And there was no significant difference in overall survival between radiotherapy and surgery, even among the different pre-EBV statuses (P > 0.05). In terms of long-term toxic and side effects, the incidence of radioactive temporal lobe injury in the radiotherapy group was higher than that in the surgery group (35.3% vs 8.2%, P < 0.001), and no statistically significant difference was found in other long-term toxic and side effects.
1 | INTRODUCTION

Nasopharyngeal carcinoma (NPC) is prevalent in Southeast Asia. Globally, there were an estimated 86,700 new cases of NPC and 50,800 deaths in 2012. The endemic form of this disease is invariably associated with prior Epstein-Barr virus (EBV) infection. Clinical outcomes have improved dramatically over the past three decades because of advances in disease management. Many studies have demonstrated that EBV can be widely detected in the primary and metastatic cancer cells of almost every patient with NPC. Additionally, the plasma EBV DNA load has been demonstrated to be correlated with tumor burden, since plasma EBV DNA may derive from the cancer cells.

Up to now, high levels of pre- and posttreatment plasma EBV DNA load were associated with poor survival outcomes. Pretreatment plasma EBV DNA was detectable (>0 copy/mL) in 53.9-93.0% of patients with NPC, and it was closely related to clinical stage and treatment outcomes. During posttreatment follow-up, plasma EBV DNA has considered to be a good marker for predicting distant metastasis and overall survival (OS) but not locoregional recurrence in patients with NPC.

With improvements in radiation therapy techniques, diagnostic imaging and concurrent chemotherapy in loco-regionally advanced disease, treatment outcomes and disease control rates have been improved substantially. However, local recurrence and distant metastasis remain as the main causes of treatment failure. Local recurrence still occurs in 5%-10% of the NPC patients, even when treated with advanced techniques such as intensity modulated radiation therapy (IMRT). Our previous study of long-term outcomes and prognostic factors of re-irradiation for locally recurrent NPC indicated that salvage re-irradiation by IMRT improve local tumor control and prolong patient survival.

In the practice, patients who suffered from recurrent NPC sometimes have consistently undetectable plasma EBV DNA when diagnosed with locoregional recurrent NPC (IrNPC) that develops second tumor recurrence or distant failure or death, whereas some patients with elevated EBV DNA levels remain disease-free even after long-term follow-up. Moreover, a recent study by Weng et al. retrospectively investigated sixty-two patients with local residual or recurrent NPC treated with endoscopic nasopharyngectomy plus chemoradiotherapy (CRT) or with CRT alone, which concluded that pre-retreatment serum EBV-DNA level was associated with disease prognosis, and patients with local intermediate- and late-stage rNPC, especially those negative for EBV-DNA, may consider opting for surgery followed by postoperative adjuvant radiotherapy or chemotherapy.

However, there was no convincing large-scale study to evaluate the characteristics of pre-retreatment plasma EBV DNA level for patients diagnosed with IrNPC. Additionally, the evidence of the value of pre-retreatment plasma EBV DNA in patients with IrNPC has not yet been described and demonstrated. Therefore, we performed this retrospective study to further investigate the clinical features and value of pre-retreatment plasma EBV DNA for predicting prognosis in patients with IrNPC.

Conclusions: The positive rate of pre-retreatment plasma EBV DNA in IrNPC is lower than primary NPC. The prognosis of EBV DNA negative group is better than positive group. For locally early-stage IrNPC, regardless of EBV DNA status, radiotherapy and surgery are available options and both can achieve better long-term survival.

KEYWORDS
clinical characteristics, Epstein-Barr Virus DNA, prognostic, recurrent nasopharynx
2.2 | Clinical staging

Routine staging included a complete medical history, physical examination, magnetic resonance imaging (MRI) of the skull base and entire neck, chest and abdominal computed tomography (CT), a whole-body bone scan, and 18F-fluorodeoxyglucose (18F-FDG) PET/CT if indicated. All patients were restaged according to the 8th edition of the Union for International Cancer Control and American Joint Committee on Cancer (AJCC) staging system. Two radiologists separately evaluated scans to assure that all medical images had minimal heterogeneity in restaging, and disagreements were resolved by consensus.

2.3 | Real-time quantitative EBV DNA PCR

Measurement of plasma EBV DNA used real-time quantitative PCR. Samples of peripheral blood (5 mL each) were collected and centrifuged at 1600 g for isolation of plasma. DNA from plasma samples was extracted with the QIAamp Blood Kit (Qiagen, Hilden, Germany) and measured using a real-time quantitative polymerase chain reaction assay amplifying the BamHI-W region of the EBV genome. The sequences of the forward and reverse primers were 5’-GCCAG AGGTA AGTGG ACTTT-3’ and 5’-TACCA CCTCC TCTTC TTGCT-3’, respectively. In our institution, a plasma EBV DNA concentration of <0 copies/mL was defined as undetectable.

2.4 | Clinical treatment

The treatment regimens of recruited patients included radiotherapy (RT), CRT, surgery (S), S + CRT, and chemotherapy (CT). The RT technology was IMRT, and the planning target volume (PTV) doses were 60-70 Gy at 1.8-2.3 Gy/fraction. Chemotherapy included adjuvant chemotherapy, concurrent chemotherapy, and neo-adjuvant chemotherapy, which were mainly cisplatin-based. Surgery mainly included nasopharyngectomy and selective cervical lymph node dissection. Various surgical approaches for nasopharyngectomy included open maxillary-swing nasopharyngectomy, endoscopic resection or trans-oral resection.

2.5 | Follow-up

Follow-up was measured from the first day of therapy to the last examination or death. Patients were examined at least every three months during the first two years, with follow-up examinations every six months thereafter until death. The routine follow-up workup included physical examination, plasma EBV DNA assay, nasopharyngeal fiberoptic endoscopy, nasopharyngeal and neck MRI, chest X-ray or computed tomography (CT), liver ultrasound or CT, whole-body bone scan, and 18F-FDG-PET/CT if necessary. The end points (time to first defining event) were locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and OS, and OS was set as the primary endpoint.

2.6 | Statistical analysis

Life-table estimation was performed according to the method of Kaplan-Meier. Univariate comparison of survival curves was performed with the use of log-rank test. The multivariate Cox proportional hazards model was used to estimate hazard ratios (HR) and 95% confidence intervals (CI). All statistical tests were two-sided, and differences with \( P < 0.05 \) were considered statistically significant.

Variables in this study included age, sex, Karnofsky Performance Status (KPS), presence of severe late complications, disease-free interval, recurrent T stage, recurrent N stage, recurrent clinical stage, treatment regimen, and pre-retreatment EBV status. The relation between the plasma EBV DNA concentration and the baseline data was evaluated with the use of a chi-square test. All statistical tests were two-sided, and a \( p \) value of less than 0.05 was considered to indicate statistical significance. Analyses were performed with the use of SPSS software (version 20.0, SPSS Inc, Chicago, IL, USA).

3 | RESULTS

3.1 | Patient characteristics

A total of 401 patients treated between April 2008 and August 2016 were retrospectively enrolled. We conducted group comparisons, univariate and multivariate analysis and subgroup analyses based on all 401 eligible cases (Figure 1). The clinical characteristics are summarized in Table 1. In the entire cohort, 197 (49.1%) patients with detectable pre-retreatment plasma EBV DNA when diagnosed with lNPC were classified as the pre EBV-positive group, and the remaining with undetectable were classified as the pre EBV-negative group. The median follow-up time for this entire cohort was 32 months (range 3-118 months). Median age was 46 years (range 22-76 years), and 308 (76.8%) patients were male. In terms of the host factors, gender, age, KPS, disease-free interval, and presence of severe late complications were similar between the pre EBV-positive group and pre EBV-negative group (\( P > 0.05 \)). However, more patients in the pre EBV-positive group had tumor burdens classified as rT4 (\( P < 0.001 \)), rN1-3 (\( P = 0.004 \)) and recurrent clinical stage IVA (\( P < 0.001 \)) as compared with the pre EBV-negative group.

3.2 | Pre-retreatment plasma EBV DNA level

The mean concentration of EBV DNA in plasma from the patients with nasopharyngeal carcinoma was 14416.9 copies/mL.
mL (range, 0-640 000). The mean pretreatment plasma EBV DNA levels were described as stratified by different recurrent classifications. Advanced recurrent T category, recurrent N category, and recurrent clinical stage had higher mean pre-retreatment plasma EBV DNA levels ($P < 0.001$; Table 2).

### 3.3 Treatment outcomes and failure patterns

The outcomes of failure patterns and mean pre-retreatment plasma EBV DNA levels of different disease status are shown in Table 3. The patient who developed distant metastatic had higher mean pre-retreatment plasma EBV DNA levels than the patient who only developed second locoregional failure. By the last follow-up, 82 (41.6%) patients in the pre EBV-positive group and 50 (24.5%) patients in the pre EBV-negative group suffered from second locoregional failure, and 24 (12.2%) patients in the pre EBV-positive group and 14 (6.9%) patients in the pre EBV-negative group developed distant metastatic failure. There was a significant difference observed between the two groups in second locoregional failure ($P = 0.01$). However, there was no significant difference observed between the two groups in distant metastatic failure ($P = 0.098$). The pre EBV-positive group had a higher percentage of cancer-related death ($P = 0.035$).

### 3.4 Univariate analysis and multivariate analysis

From the univariate analysis, we found that pre EBV-positive status was correlated with poorer clinical outcomes significantly. The 3-year LRRFS, DMFS, and OS rates for the entire cohort were 64.8%, 89.4%, and 58.8%, respectively. The estimated 3-year LRRFS, DMFS and OS rates for pre EBV-positive group vs the pre EBV-negative group were 54.2%
| Characteristic            | Pre<sup>a</sup> EBV-negative No. (%) | Pre EBV-positive No. (%) | p<sup>b</sup> |
|--------------------------|-------------------------------------|-------------------------|--------------|
| Gender                   |                                     |                         | 0.525        |
| Male                     | 154 (75.5)                          | 154 (78.2)              |              |
| Female                   | 50 (24.5)                           | 43 (21.8)               |              |
| Age (years)              |                                     |                         | 0.334        |
| ≤45                      | 102 (50.0)                          | 89 (45.2)               |              |
| >45                      | 102 (50.0)                          | 108 (54.8)              |              |
| KPS                      |                                     |                         | 0.980        |
| ≥90                      | 152 (74.5)                          | 147 (74.6)              |              |
| <90                      | 52 (25.4)                           | 50 (25.4)               |              |
| DFI (months)<sup>c</sup> |                                     |                         | 0.266        |
| 0-12                     | 36 (17.6)                           | 29 (14.7)               |              |
| 13-24                    | 64 (31.4)                           | 49 (24.9)               |              |
| 25-36                    | 37 (18.1)                           | 38 (19.3)               |              |
| >36                      | 67 (32.9)                           | 81 (41.1)               |              |
| Presence of severe late complications |                   |                         | 0.228        |
| Yes                      | 55 (27.0)                           | 56 (28.4)               |              |
| No                       | 149 (73.0)                          | 141 (71.6)              |              |
| Recurrent T stage<sup>d</sup> |                               |                         | <0.001       |
| rT0-1                    | 66 (32.4)                           | 40 (20.3)               |              |
| rT2                      | 25 (12.3)                           | 17 (8.6)                |              |
| rT3                      | 75 (36.7)                           | 71 (36.1)               |              |
| rT4                      | 38 (18.6)                           | 69 (35.0)               |              |
| Recurrent N stage<sup>d</sup> |                               |                         | 0.004        |
| rN0                      | 129 (63.2)                          | 94 (47.7)               |              |
| rN1                      | 63 (30.9)                           | 76 (38.6)               |              |
| rN2                      | 11 (5.4)                            | 21 (10.6)               |              |
| rN3                      | 1 (0.5)                             | 6 (3.1)                 |              |
| Recurrent clinical stage<sup>d</sup> |                                 |                         | <0.001       |
| rI                       | 28 (13.7)                           | 9 (4.6)                 |              |
| rII                      | 57 (28.0)                           | 33 (16.8)               |              |
| rIII                     | 81 (39.7)                           | 82 (41.6)               |              |
| rIVA                     | 38 (18.6)                           | 73 (37.0)               |              |
| Treatment regimen        |                                     |                         | 0.011        |
| RT alone                 | 25 (12.3)                           | 12 (6.1)                |              |
| CRT                      | 92 (45.1)                           | 116 (58.9)              |              |
| S alone                  | 64 (31.4)                           | 41 (20.8)               |              |
| S + CRT                  | 8 (3.9)                             | 12 (6.1)                |              |
| CT alone                 | 15 (7.3)                            | 16 (8.1)                |              |

Abbreviations: AJCC, American Joint Committee on Cancer; CT, chemotherapy; CRT, chemoradiotherapy; EBV, Epstein-Barr virus; KPS, Karnofsky Performance Status; RT, radiotherapy; S, surgery; UICC, Union for International Cancer Control.

<sup>a</sup>Pre, pre-retreatment.

<sup>b</sup>P values were calculated using the chi-square test or Fisher exact test if indicated.

<sup>c</sup>DFI, Disease-free interval was defined from the date of completion of treatment to diagnosis of recurrence or final follow-up if sooner.

<sup>d</sup>According to the 8th edition of the AJCC/UICC staging system.
vs 75.0% (P < 0.001), 86.6% vs 91.9% (P = 0.05), 51.6% vs 65.9% (P = 0.01), respectively, (Figure 2). The 3-year OS rates for staged rI, rII, rIII, and rIVA were 93.5%, 77.3%, 56.4%, and 58.8%, respectively.

In multivariate analysis including gender, age, KPS, presence of severe late complications, disease-free interval, recurrent T category, recurrent N category, recurrent clinical stage, treatment regimen and pre EBV status as covariates, pre EBV status was an independent prognostic factor for LRRFS (HR, 1.95; 95% CI, (1.36-2.79); P < 0.001). The pre EBV-positive group had worse DMFS and OS than the pre EBV-negative group. However, pre EBV status was not an independent prognostic factor for DMFS. Moreover, recurrent N category was an independent prognostic factor for DMFS. Gender, recurrent T category, and presence of severe late complications were independently associated with an increased risk of death. The findings from univariate and multivariate analyses are summarized in Table 4.

3.5 Subgroup analysis of treatment regimen stratified by pre EBV status

In this study, there were 66 of 401 patients with an rI + rII stage. Among these, 17 (25.8%) patients accepted RT alone and 49 (74.2%) received S alone. There was no significant difference between RT and S in LRRFS, DMFS, or OS (all P > 0.05; Figure 3). Moreover, we stratified these patients according to the pre EBV status. There were 49 patients who were pre EBV-negative and 17 patients who were pre EBV-positive. Additionally, there were no significant differences in OS between RT and S in the pre EBV-negative group or the pre EBV-positive group (both P > 0.05; Figure 4.).

4 DISCUSSION

In general, the clinical value of pretreatment EBV DNA in patients with primary NPC has been widely demonstrated. The value of pre-retreatment plasma EBV DNA in patients with lrNPC has not yet been evaluated before, and this study is the first one to describe the level of pre-retreatment plasma EBV on survival of patients with lrNPC. A recent study by Chan et al. showed that the plasma EBV DNA level was correlated with T category and resection margin status in a cohort of 60 patients with lrNPC and to assess the prognostic value of pre-retreatment plasma EBV on survival of patients with lrNPC. The mean concentration of preoperative plasma EBV DNA was associated with tumor load (T1: 48 copies/mL, T2: 316 copies/mL, T3:890 copies/mL, P = 0.03). With the above-mentioned findings, plasma EBV DNA concentration can reflect the tumor load burden in NPC. In the present study, it was also applied to lrNPC. The mean pre-retreatment plasma EBV DNA has strong relations with recurrent T category, recurrent N category, and recurrent clinical stage, and the patient with advanced-stage lrNPC had higher levels of pre-retreatment plasma EBV DNA (all P < 0.001). According to previous studies, pre-treatment plasma EBV DNA was detectable (>0 copy/mL) in 53.9%–93% of patients with NPC. In contrast, in this study, pre-retreatment plasma EBV DNA was detectable (>0 copy/mL) in 49.1% of patients with lrNPC, which was lower than primary NPC. The mechanism is still unknown to us, and an explanation is that locoregionally recurrent cancer cells often regrow from irradiated sites. Post-irradiation changes such as stromal fibrosis and decreased vascularity may interfere with the release of EBV DNA into the plasma.

Recent studies demonstrated that the presence of severe late complications, rT3-4 category and tumor volume were independent prognostic factors for OS in patients with rNPC. However, in primary NPC, there was a finding that patients with small tumor volume and high EBV DNA level had a worse prognosis than those with large tumor and low EBV DNA level. Patients with low EBV DNA levels, and

### TABLE 2 Pre-retreatment plasma EBV DNA level in patients with locoregional recurrent nasopharyngeal carcinoma of different recurrent classifications

| Recurrent classification | No. | Mean pre-retreatment plasma EBV DNA (copies/ml) | P* |
|--------------------------|-----|---------------------------------------------|----|
| Recurrent T category b   |     |                                            |    |
| rT0-1                    | 106 | 4905.6                                     | <0.001 |
| rT2                      | 42  | 11206.9                                    |    |
| rT3                      | 146 | 13574.8                                    |    |
| rT4                      | 107 | 26248.3                                    |    |
| Recurrent N category b   |     |                                            | <0.001 |
| rN0                      | 223 | 6396.4                                     |    |
| rN1                      | 139 | 14300.7                                    |    |
| rN2                      | 32  | 36469.7                                    |    |
| rN3                      | 7   | 171422.9                                   |    |
| Recurrent clinical stage b |   |                                            | <0.001 |
| rI                       | 39  | 535.9                                      |    |
| rII                      | 89  | 4745.2                                     |    |
| rIII                     | 162 | 12188.9                                    |    |
| rIVA                     | 111 | 30300.4                                    |    |

Abbreviations: AJCC, American Joint Committee on Cancer; UICC, Union for International Cancer Control.

*P values were calculated using the chi-square test or Fisher exact test if indicated.

bAccording to the 8th edition of the AJCC/UICC staging system.
either small or large tumor volumes, had favorable prognosis. A recent study showed that high levels of pre EBV with early stage (I + II) disease demonstrated higher OS than low levels of pre EBV with advanced stage (III + IVAB) disease, but not DMFS in newly diagnosed NPC. Thus, the value of plasma EBV DNA and recurrent overall stage for predicting survival outcomes are still controversial in patients with lrNPC. In this study, subgroup analysis of survival outcomes according to the 8th edition of the AJCC also demonstrated that advanced recurrent T category and recurrent clinical stage were associated with poorer survival (both $P < 0.001$).

A study by An X et al. reported that metastatic/recurrent NPC patients with low pretreatment plasma EBV DNA level and undetectable posttreatment plasma EBV DNA showed a favorable prognosis (5-year OS was 50.6%), which indicated that plasma EBV DNA had predictive value for prognosis in metastatic/recurrent NPC patients undergoing palliative chemotherapy. Moreover, in our study, the outcomes of univariate analysis may be less convincing on account of the unbalanced distribution of recurrent tumor stage and treatment protocols, while there are no exactly standard therapeutic modalities in patients with lrNPC. With the developed surgical technology, nasopharyngectomy is recommended for early stage resectable disease. Comparing the efficacy of surgery with re-irradiation is difficult as patients eligible for surgery generally have earlier stage disease (usually rT1-2), smaller tumor volume and fewer comorbidities. There was no randomized controlled study comparing the two modalities, but retrospective case series suggested that their local control rates were probably similar if dealing with the same group of patients.

Some recent studies showed that $^{125}$I brachytherapy was a feasible, safe, and effective treatment for locally recurrent NPC, and the 3D high-definition endoscopic system improves the precision of endoscopic nasopharyngectomy.

### TABLE 3

Pre-retreatment plasma EBV DNA of disease status in pre EBV-negative and pre EBV-positive patients with locoregional recurrent NPC

| Disease status | Mean prea plasma EBV DNA (copies/ml) | Pre EBV-negative No. (%) | Pre EBV positive No. (%) | $P^b$ |
|----------------|------------------------------------|--------------------------|-------------------------|-------|
| Locoregional only | 9379.9 | 41 (38.7) | 65 (32.9) | 0.025 |
| Distant only | 2524.5 | 5 (2.5) | 7 (3.6) | 0.530 |
| Locoregional + distant | 64496.2 | 9 (4.4) | 17 (8.6) | 0.108 |
| Total locoregional | 20236.1 | 50 (24.5) | 82 (41.6) | 0.010 |
| Total distant | 52100.9 | 14 (6.9) | 24 (12.2) | 0.098 |
| Total | 20653.5 | 55 (27.0) | 89 (45.2) | 0.009 |
| Death | | | | 0.035 |
| Yes and due to cancer | 21321.5 | 104 (51.0) | 121 (61.4) | |
| No | 5590.0 | 100 (49.0) | 76 (38.6) | |

$a$ pre, pre-retreatment.  
$b$ $P$ values were calculated using the chi-square test or Fisher exact test if indicated.

### FIGURE 2

Kaplan-Meier LRRFS. (A) DMFS (B) and OS (C) curves for locoregional recurrent NPC patients classified into pre-retreatment EBV-negative and pre-retreatment EBV-positive groups. LRRFS, local-regional relapse-free survival; DMFS, distant metastasis-free survival; OS, overall survival.
particularly when dissection of the internal carotid artery and dura is required. With advances in technology, the appropriate treatment protocol for patients with detected pre EBV DNA may need further study. Additionally, the results of multivariate analysis showed that patients with undetected pre EBV DNA have an obviously better prognosis than patients with detected pre EBV DNA, and recurrent clinical stage is as ever the most significant prognostic factor for OS. Pre EBV DNA status is an independent prognostic factor for LRRFS, but not DMFS or OS in lrNPC, which is different from primary NPC. Moreover, recurrent clinical stage was also an independent prognostic factor for LRRFS, which is similar to primary NPC. Additionally, early PET-CT response and plasma EBV DNA clearance could predict survival and subsequent response to chemotherapy in patients with advanced or recurrent NPC. Here, findings indicate that the high level of pre-retreatment plasma EBV DNA may imply the possibility for second recurrent failure and poor OS, which hints at
more careful examinations, such as a whole-body scan (eg, PET/CT) and routine follow-up EBV DNA assays may need to be performed at regular intervals.

Investigation of EBV miRNA target genes revealed the inhibition of tumor suppressor genes and upregulation of multiple EBV-encoded miRNAs in NPC. The BART miRNA cluster was related to the expression of LMP1, Zp, gp350, and EBNA1. Chan et al demonstrated that tissue EBV microRNA BART7 is useful for identifying a subgroup of patients with histologically clear margins who were at increased risk of subsequent local tumor recurrence. Considering the finding that patients with lrNPC and high EBV DNA levels were at greater risk of second local recurrence. Latent infection is known to be necessary for virus persistence and immune evasion and the EBV after lysis will express a large number of viral proteins to induce immune recognition and attack, so maintaining stable latent infection is an important means of EBV immune escape. And the challenge in treating lrNPC of the development of an effective EBV vaccine as an immunotherapeutic strategy for primary and recurrent NPC may be important and needed in the future.

Moreover, the present study has several limitations. First, biases due to the retrospective nature of the analyses are unavoidable when the follow-up time is inadequate and it was a single-center study. Second, not all of the patients with tumor recurrence underwent histologic examinations or PET/CT scans. Despite these limitations above, the highlights of this study are that it is the first large-scale study to evaluate the importance of pre-retreatment EBV DNA and its value for predicting survival. In summary, future prospective, multicenter clinical studies should be warranted to verify the results of this current study.

5 | CONCLUSIONS

The positive rate of pre-retreatment plasma EBV DNA in lrNPC is lower than primary NPC. The prognosis of EBV DNA negative group is better than positive group. For locally early-stage lrNPC, regardless of EBV DNA status, radiotherapy and surgery are available options and both can achieve better long-term survival.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID

Ming-Zhu Liu https://orcid.org/0000-0003-2430-6517

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
2. Chua ML, Chan AT. Gemcitabine: a game changer in nasopharyngeal carcinoma. Lancet. 2016;388(10054):1853-1854.
3. Lee A, Ma B, Ng WT, Chan A. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356-3364.
4. Sun Z, Xiao C, Jiang W, Feng X, Liu Y. Comparison of Epstein-Barr virus in nasopharynx tissue and desquamating cell for diagnosis of nasopharyngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006;20(4):153-154.
5. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. 1995;146(6):1355-1367.
6. Lin J-C, Wang W-Y, Chen KY, et al. Correlation of Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461-2470.
7. Mäkitie AA, Reis PP, Irish J, et al. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck. 2004;26(9):815-822.
8. Peng H, Chen L, Zhang Y, et al. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget. 2016;7(17):24208-24216.

FIGURE 4 Kaplan-Meier Effect of treatment regimen on survival outcomes in patients with rI+rII stage and stratified by different pre-retreatment EBV statuses. Kaplan–Meier overall survival: (A) for patients with undetectable pre-retreatment EBV and (B) for patients with detectable pre-retreatment EBV stratified by RT alone or S alone. OS, overall survival; RT, radiotherapy; S, surgery.
9. Fan H, Schichman SA, Swinnen LJ, et al. Analytic validation of a competitive polymerase chain reaction assay for measuring Epstein-Barr viral load. *Diagn Mol Pathol*. 2001;10(4):255-264.

10. Shao JY, Zhang Y, Li YH, et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. *Anticancer Res*. 2004;24(6):4059-4066.

11. Hou X, Zhao C, Guo Y, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. *Clin Oncol (R Coll Radiol)*. 2011;23(2):128-133.

12. Chan A, Hui EP, Ngan R, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. *J Clin Oncol*. 2018;36:3091-3100. JCO2018777847

13. Chan K, Woo J, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. *N Engl J Med*. 2017;377(6):513-522.

14. Chen M, Yin L, Jing WU, et al. Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma. *Biomed Res Int*. 2015;2015:1-5. 617949.

15. Chen W-H, Tang L-Q, Guo S-S, et al. Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era. *Medicine (Baltimore)*. 2016;95(5):e2642.

16. Liu T-B, Zheng Z-H, Pan J, Pan L-L, Chen L-H. Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis. *Clin Invest Med*. 2017;40(1):E1-E12.

17. Prayongrat A, Chakkabat C, Kannarunimit D, Hansasuta P, Lerbtutsayanukul C. Prevalence and significance of plasma Epstein-Barr virus DNA level in nasopharyngeal carcinoma. *J Radiat Res*. 2017;58(4):509-516.

18. Tang L-Q, Chen Q-Y, Guo S-S, et al. The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study. *Br J Cancer*. 2014;111(6):1102-1111.

19. Lu L, Li J, Zhao C, et al. Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma. *Oral Oncol*. 2016;60:18-24.

20. Lan M, Chen C, Huang Y, et al. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr Virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. *Oncotarget*. 2016;7(29):46242-46252.

21. Li W-F, Zhang Y, Huang X-B, et al. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy. *Chin J Cancer*. 2017;36(1):87.

22. Leung SF, Chan K, Ma BB, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. *Ann Oncol*. 2014;25(6):1204-1208.

23. Ng WT, Lee M, Hung WM, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys*. 2011;79(2):420-428.

24. Setton I, Han J, Kannarunimit D, et al. Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. *Oral Oncol*. 2016;53:67-73.

25. Lee A, Ng WT, Chan L, et al. Evolution of treatment for nasopharyngeal cancer—success and setback in the intensity-modulated radiotherapy era. *Radiother Oncol*. 2014;110(3):377-384.

26. Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. *Radiother Oncol*. 2014;110(3):398-403.

27. Wang R, Wu F, Lu H, et al. Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study. *J Cancer Res Clin Oncol*. 2013;139(1):139-145.

28. Han F, Zhao C, Huang S-M, et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. *Clin Oncol (R Coll Radiol)*. 2012;24(8):569-576.

29. Weng J, Wei J, Si J, et al. Clinical outcomes of residual or recurrent nasopharyngeal carcinoma treated with endoscopic nasopharyngectomy plus chemoradiotherapy or with chemoradiotherapy alone: a retrospective study. *PeerJ*. 2017;5:e3912.

30. Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. *Ann Surg Oncol*. 2018;25(4):845-847.

31. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. *Cancer Res*. 1999;59(6):1188-1191.

32. Stevens SJ, Vervoort MB, van den Brule AJ, Meenhorst PL, Meijer CJ, Middeldorp JM Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR. *J Clin Microbiol*. 1999;37(9):2852-2857.

33. Chan JY, Wong ST. The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma. *Laryngoscope*. 2014;124(1):126-130.

34. Tian Y-M, Huang W-Z, Yuan X, Bai L, Zhao C, Han F. The challenge in treating locally recurrent T3–4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy. *Oncotarget*. 2017;8(26):43450-43457.

35. Li YQ, Tian YM, Tan SH, et al. Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy. *J Clin Oncol*. 2018;36(9):891-899.

36. Yue Q, Zhang M, Chen Y, Zheng D, Chen Y, Feng M. Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: a meta-analysis. *Oncol*. 2018;81:81-88.

37. He S-S, Wang Y, Bao Y, et al. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study. *Cancer Med*. 2018;7(4):1110-1117.

38. An X, Wang F-H, Ding P-R, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. *Cancer*. 2011;117(16):3750-3757.

39. Yu KH, Leung SF, Tung SY, et al. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. *Head Neck*. 2005;27(5):397-405.
40. Lee A, Fee WE, Ng WT, Chan LK. Nasopharyngeal carcinoma: salvage of local recurrence. *Oral Oncol.* 2012;48(9):768-774.
41. Yan H, Mo Z, Xiang Z, et al. CT-guided (125)I brachytherapy for locally recurrent nasopharyngeal carcinoma. *J Cancer*. 2017;8(11):2104-2113.
42. Chan J, Wei WI. Three-dimensional endoscopy for endoscopic salvage nasopharyngectomy: preliminary report of experience. *Laryngoscope*. 2018;128(6):1386-1391.
43. Ma B, Hui EP, King A, et al. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. *Br J Cancer*. 2018;118(8):1051-1055.
44. Wong A, Kong KL, Tsang J, Kwong D, Guan X-Y. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. *Cancer*. 2012;118(3):698-710.
45. Correia S, Palser A, Elgueta Karsteeg C, et al. Natural variation of Epstein-Barr virus genes, proteins, and primary microRNA. *J Virol*. 2017;91(15):e00375-17.
46. Chan JY, Wong ST, Wei WI. The role of Epstein-Barr virus-encoded microRNA BART7 status of resection margins in the prediction of local recurrence after salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma. *Cancer*. 2015;121(14):2358-2366.
47. Xiang T, Lin Y-X, Ma W, et al. Vasculogenic mimicry formation in EBV-associated epithelial malignancies. *Nat Commun*. 2018;9(1):5009.

**How to cite this article:** Liu M-Z, Fang S-G, Huang W, et al. Clinical characteristics and prognostic value of pre-retreatment plasma Epstein-Barr virus DNA in locoregional recurrent nasopharyngeal carcinoma. *Cancer Med*. 2019;8:4633–4643. [https://doi.org/10.1002/cam4.2339](https://doi.org/10.1002/cam4.2339)